GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Evaxion Biotech AS EVAX · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.75

-8.33%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Evaxion Biotech AS

Its shares trade under the ticker EVAX. It has been listed since 5 February 2021. In the fiscal year to 31 December 2025, it reported revenue of $7.5m and a net loss of $7.7m. At that date it held total assets of $28.4m and shareholders' equity of $17.0m.

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
5 Feb 2021
Employees
45
Website
evaxion.ai ↗
Head office
DR NEERGAARDS VEJ 5F, HOERSHOLM
Incorporated in
G7
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company develops AI-powered immunology vaccines with multiple clinical-stage programs.
  • Has a diverse pipeline including phase 2 and phase 1 trials for various cancer treatments.
  • Operates with a small team of 45 employees focused on specialized biotech research.

Weaknesses

  • Company name changed to Evaxion A/S in May 2025, indicating potential rebranding challenges.
  • All programs are in early to mid-stage clinical development without approved products.
  • Relies on a small employee base of 45 for all research and development activities.

Opportunities

  • Expanding AI-powered vaccine development could attract significant investment.
  • Growing demand for cancer treatments may increase market opportunities.
  • Potential for partnerships with larger pharmaceutical companies for clinical trials.

Threats

  • Clinical trial failures could delay or halt development of key vaccine candidates.
  • Competition in the biotech sector may limit market share for new vaccines.
  • Regulatory hurdles could impact the approval timeline for new treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.